Chunk #16 — 3. Pharmacogenetic Studies of Treatment for Alcohol Use Disorder in Individuals of Diverse Ancestries — 3.1 Individuals of European Ancestry
per drinking day were lower and percent days abstinent were higher compared to LS/SS participants. An additional benefit was seen in individuals who were TT homozygotes of the rs1042173 SNP in the same gene, such that SLC6A4-LL/TT individuals had the greatest proportion of abstinent days and lowest drinks/drinking day compared to individuals with other allele combinations. Within this same sample, the authors investigated the possibility of using multiple genotype combinations to better predict ondansetron treatment outcomes.40 Among several polymorphisms in the 5-hydroxytryptamine receptor 3A (HTR3A) and receptor 3B (HTR3B) genes, they found possession of one of three additional genotypes, HTR3A-rs1150226-AG, HTR3A-rs1176713-GG, and/or HTR3B-rs17614942-AC, in combination with the genotype identified in the previously mentioned study (i.e. SLC6A4-LL/TT) was associated with better ondansetron treatment response.
